201 related articles for article (PubMed ID: 34952640)
21. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
22. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
[TBL] [Abstract][Full Text] [Related]
23. Imaging predictors of 4q12 amplified and RB1 mutated glioblastoma IDH-wildtype.
Dono A; Torres J; Nunez L; Arevalo O; Rodriguez-Quinteros JC; Riascos RF; Kamali A; Tandon N; Ballester LY; Esquenazi Y
J Neurooncol; 2024 Mar; 167(1):99-109. PubMed ID: 38351343
[TBL] [Abstract][Full Text] [Related]
24. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors.
Cantero D; Mollejo M; Sepúlveda JM; D'Haene N; Gutiérrez-Guamán MJ; Rodríguez de Lope Á; Fiaño C; Castresana JS; Lebrun L; Rey JA; Salmon I; Meléndez B; Hernández-Laín A
Neurooncol Adv; 2020; 2(1):vdz059. PubMed ID: 32642724
[TBL] [Abstract][Full Text] [Related]
25. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
26. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H
Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247
[TBL] [Abstract][Full Text] [Related]
27. Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Shibahara I; Sonoda Y; Suzuki H; Mayama A; Kanamori M; Saito R; Suzuki Y; Mashiyama S; Uenohara H; Watanabe M; Kumabe T; Tominaga T
Brain Tumor Pathol; 2018 Jan; 35(1):10-18. PubMed ID: 29138945
[TBL] [Abstract][Full Text] [Related]
28. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
29. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.
Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S
J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679
[TBL] [Abstract][Full Text] [Related]
30. pRB immunostaining in the differential diagnosis between pleomorphic xanthoastrocytoma and glioblastoma with giant cells.
Barresi V; Simbolo M; Ciaparrone C; Pedron S; Mafficini A; Scarpa A
Histopathology; 2022 Nov; 81(5):661-669. PubMed ID: 35945679
[TBL] [Abstract][Full Text] [Related]
31. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
32. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
[TBL] [Abstract][Full Text] [Related]
33. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma.
Stasik S; Juratli TA; Petzold A; Richter S; Zolal A; Schackert G; Dahl A; Krex D; Thiede C
Neoplasia; 2020 Dec; 22(12):800-808. PubMed ID: 33142244
[TBL] [Abstract][Full Text] [Related]
34. A longer time to relapse is associated with a larger increase in differences between paired primary and recurrent IDH wild-type glioblastomas at both the transcriptomic and genomic levels.
Ho WM; Chen CY; Chiang TW; Chuang TJ
Acta Neuropathol Commun; 2024 May; 12(1):77. PubMed ID: 38762464
[TBL] [Abstract][Full Text] [Related]
35. Distribution and favorable prognostic implication of genomic EGFR alterations in IDH-wildtype glioblastoma.
Higa N; Akahane T; Hamada T; Yonezawa H; Uchida H; Makino R; Watanabe S; Takajo T; Yokoyama S; Kirishima M; Matsuo K; Fujio S; Hanaya R; Tanimoto A; Yoshimoto K
Cancer Med; 2023 Jan; 12(1):49-60. PubMed ID: 35695190
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
37. Gemistocytes in newly diagnosed glioblastoma multiforme: Clinical significance and practical implications in the modern era.
Laviv Y; Berkowitz S; Kanner AK; Fichman S; Benouaich-Amiel A; Siegal T; Yust-Katz S
J Clin Neurosci; 2021 Jun; 88():120-127. PubMed ID: 33992170
[TBL] [Abstract][Full Text] [Related]
38. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
Oh JE; Ohta T; Nonoguchi N; Satomi K; Capper D; Pierscianek D; Sure U; Vital A; Paulus W; Mittelbronn M; Antonelli M; Kleihues P; Giangaspero F; Ohgaki H
Brain Pathol; 2016 Jul; 26(4):517-22. PubMed ID: 26443480
[TBL] [Abstract][Full Text] [Related]
39. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
40. Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients.
Neumann JE; Dorostkar MM; Korshunov A; Mawrin C; Koch A; Giese A; Schüller U
J Neuropathol Exp Neurol; 2016 May; 75(5):408-14. PubMed ID: 26975364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
